Market Overview:
The global non-oncology biopharmaceuticals market is expected to register a CAGR of 10.8% during the forecast period (2018–2030). The market growth can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and technological advancements in the field of biopharmaceuticals. Based on type, the global non-oncology biopharmaceuticals market is segmented into biologics and biosimilars. The biosimilars segment is expected to register a higher CAGR during the forecast period as compared to the biologics segment. This can be attributed to their lower cost and easy availability as compared to their branded counterparts. Based on application, the global non-oncology biopharmaceuticals market is divided into immunology, endocrinology, and others (cardiology, neurology). The immunology segment accounted for a major share of the global non-oncology biopharmaceuticals market in 2017 and is projected to maintain its dominance duringthe forecast period. This can be attributedto increasing prevalenceof autoimmune diseases such as rheumatoid arthritisand Crohn’sdisease acrossthe globe.Geographically speaking, North America held majority share of th eglobalnon - onco logybiop harmaceuti calsmarketin2017 .
Product Definition:
Non-oncology biopharmaceuticals are pharmaceutical drugs that are used to treat conditions and diseases that are not cancer-related. These drugs can be used to treat a variety of conditions, including autoimmune disorders, cardiovascular disease, and respiratory illnesses. The importance of non-oncology biopharmaceuticals lies in the fact that they can improve the quality of life for patients who suffer from these other serious medical conditions.
Biologics:
Biologics are living organisms or products derived from living organisms and used as therapeutic agents. They are different from synthetic or inorganic chemicals because they originate from natural sources, e.g., antibodies, interferons, growth factors etc. Biologics have been observed to be more effective than chemical therapies in most cases; this is the major factor driving the market for biologics usage in non-oncology biopharmaceuticals market globally.
Biosimilars:
Biosimilars are biological products that are highly similar to an approved biologic drug. They can be used as a substitute for the original drug and have similar therapeutic properties. Biosimilars can be of two types: fully bio-based and chemically synthesized biosimilars.
Application Insights:
The immunology segment dominated the global non-oncology biopharmaceuticals market in 2017. This can be attributed to the growing incidence of chronic diseases, such as cancer and autoimmune disorders. According to a study published by the WHO, it is estimated that approximately 17 million people die from chronic diseases every year globally. Moreover, according to another study published by NCBI, it is estimated that about 1 in 6 deaths occur due to cancer worldwide each year. Thus, increasing incidences of these diseases drive demand for immunotherapy drugs which are highly expensive as compared to other therapies available in the market.
However, endocrinology held a significant share owing to high prevalence of hormone-dependent conditions including diabetes mellitus and thyroid disorders across various regions including North America and Europe.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of biopharmaceutical manufacturers coupled with high R&D investment by companies is expected to drive the regional market over the forecast period. Asia Pacific is estimated to be fastest-growing region during the forecast years due to increasing healthcare expenditure and rising awareness about oncology therapeutics in emerging countries, such as China and India. Moreover, an increase in government funding for cancer research will boost growth further. For instance, according to data published by NCBI, between 2014 and 2020 Indian government has planned investing around USD X billion for cancer research every year which will propel demand for non-oncology drugs over the next eight years (Indonesia).
Moreover, growing efforts from key players are anticipated to fuel demand across this region during future years (Japan).
Growth Factors:
- Increasing prevalence of chronic diseases such as diabetes, heart disease, and arthritis is expected to drive the demand for non-oncology biopharmaceuticals.
- Rising geriatric population is also anticipated to boost the market growth in the near future.
- Growing awareness about various non-oncology biopharmaceuticals therapies among patients is projected to propel the market growth over the forecast period.
- Technological advancements in drug delivery systems are likely to create new opportunities for players operating in this market during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Non-oncology Biopharmaceuticals Market Research Report
By Type
Biologics, Biosimilars
By Application
Immunology, Endocrinology, Others
By Companies
Roche, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Novartis, Merck, Teva, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, UCB Pharma, Amgen, AbbVie, Takeda, AstraZeneca, Mylan, LEO Pharma, Boehringer Ingelheim, Alexion Pharmaceuticals, Elusys Therapeutics, Swedish Orphan Biovitrum, Biogen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
156
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Non-oncology Biopharmaceuticals Market Report Segments:
The global Non-oncology Biopharmaceuticals market is segmented on the basis of:
Types
Biologics, Biosimilars
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Immunology, Endocrinology, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Sanofi
- Johnson & Johnson
- Pfizer
- Novo Nordisk
- Novartis
- Merck
- Teva
- Eli Lilly
- Bristol-Myers Squibb
- GlaxoSmithKline
- UCB Pharma
- Amgen
- AbbVie
- Takeda
- AstraZeneca
- Mylan
- LEO Pharma
- Boehringer Ingelheim
- Alexion Pharmaceuticals
- Elusys Therapeutics
- Swedish Orphan Biovitrum
- Biogen
Highlights of The Non-oncology Biopharmaceuticals Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Biologics
- Biosimilars
- By Application:
- Immunology
- Endocrinology
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Non-oncology Biopharmaceuticals Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Non-oncology biopharmaceuticals are drugs that are not specifically designed to treat cancer, but may have other benefits for patients. These drugs may be used to treat conditions such as heart disease, arthritis, and Crohn's disease.
Some of the key players operating in the non-oncology biopharmaceuticals market are Roche, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Novartis, Merck, Teva, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, UCB Pharma, Amgen, AbbVie, Takeda, AstraZeneca, Mylan, LEO Pharma, Boehringer Ingelheim, Alexion Pharmaceuticals, Elusys Therapeutics, Swedish Orphan Biovitrum, Biogen.
The non-oncology biopharmaceuticals market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Non-oncology Biopharmaceuticals Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Non-oncology Biopharmaceuticals Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Non-oncology Biopharmaceuticals Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Non-oncology Biopharmaceuticals Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Non-oncology Biopharmaceuticals Market Size & Forecast, 2018-2028
4.5.1 Non-oncology Biopharmaceuticals Market Size and Y-o-Y Growth
4.5.2 Non-oncology Biopharmaceuticals Market Absolute $ Opportunity
Chapter 5 Global Non-oncology Biopharmaceuticals Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Non-oncology Biopharmaceuticals Market Size Forecast by Type
5.2.1 Biologics
5.2.2 Biosimilars
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Non-oncology Biopharmaceuticals Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Non-oncology Biopharmaceuticals Market Size Forecast by Applications
6.2.1 Immunology
6.2.2 Endocrinology
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Non-oncology Biopharmaceuticals Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Non-oncology Biopharmaceuticals Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Non-oncology Biopharmaceuticals Analysis and Forecast
9.1 Introduction
9.2 North America Non-oncology Biopharmaceuticals Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Non-oncology Biopharmaceuticals Market Size Forecast by Type
9.6.1 Biologics
9.6.2 Biosimilars
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Non-oncology Biopharmaceuticals Market Size Forecast by Applications
9.10.1 Immunology
9.10.2 Endocrinology
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Non-oncology Biopharmaceuticals Analysis and Forecast
10.1 Introduction
10.2 Europe Non-oncology Biopharmaceuticals Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Non-oncology Biopharmaceuticals Market Size Forecast by Type
10.6.1 Biologics
10.6.2 Biosimilars
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Non-oncology Biopharmaceuticals Market Size Forecast by Applications
10.10.1 Immunology
10.10.2 Endocrinology
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Non-oncology Biopharmaceuticals Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Non-oncology Biopharmaceuticals Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Non-oncology Biopharmaceuticals Market Size Forecast by Type
11.6.1 Biologics
11.6.2 Biosimilars
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Non-oncology Biopharmaceuticals Market Size Forecast by Applications
11.10.1 Immunology
11.10.2 Endocrinology
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Non-oncology Biopharmaceuticals Analysis and Forecast
12.1 Introduction
12.2 Latin America Non-oncology Biopharmaceuticals Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Non-oncology Biopharmaceuticals Market Size Forecast by Type
12.6.1 Biologics
12.6.2 Biosimilars
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Non-oncology Biopharmaceuticals Market Size Forecast by Applications
12.10.1 Immunology
12.10.2 Endocrinology
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Non-oncology Biopharmaceuticals Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Non-oncology Biopharmaceuticals Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Non-oncology Biopharmaceuticals Market Size Forecast by Type
13.6.1 Biologics
13.6.2 Biosimilars
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Non-oncology Biopharmaceuticals Market Size Forecast by Applications
13.10.1 Immunology
13.10.2 Endocrinology
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Non-oncology Biopharmaceuticals Market: Competitive Dashboard
14.2 Global Non-oncology Biopharmaceuticals Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche
14.3.2 Sanofi
14.3.3 Johnson & Johnson
14.3.4 Pfizer
14.3.5 Novo Nordisk
14.3.6 Novartis
14.3.7 Merck
14.3.8 Teva
14.3.9 Eli Lilly
14.3.10 Bristol-Myers Squibb
14.3.11 GlaxoSmithKline
14.3.12 UCB Pharma
14.3.13 Amgen
14.3.14 AbbVie
14.3.15 Takeda
14.3.16 AstraZeneca
14.3.17 Mylan
14.3.18 LEO Pharma
14.3.19 Boehringer Ingelheim
14.3.20 Alexion Pharmaceuticals
14.3.21 Elusys Therapeutics
14.3.22 Swedish Orphan Biovitrum
14.3.23 Biogen
